Behavioral Health Viewpoint - Drug Patent Protection.

In the case of Prozac, the marginal cost of producing an additional unit of the newer (single isomer) interpretation of the drug should be minimal, since a large firm like Lilly has extensive knowledge about fashioning the brand-name drug.
Furthermore, the pharmaceutical lot is not starting from the achiever result to develop this drug.
An experienced pharmaceutical investigating ship’s complement would morality from cost-reducing “learning-by-doing” effects acquired through geezerhood of R&D programs.
If, as the companies hope, there actually are fewer side effects for the ace isomer turn of fluoxetine, then commercialism the “new, improved” Prozac should be straightforward.
This is a part of article Behavioral Health Viewpoint - Drug Patent Protection. Taken from "Prozac Fluoxetine Generic" Information Blog